These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 25112418)

  • 21. Pituitary adenylate cyclase-activating polypeptide directly modulates the activity of proopiomelanocortin neurons in the rat arcuate nucleus.
    Mounien L; Bizet P; Boutelet I; Gourcerol G; Fournier A; Vaudry H; Jégou S
    Neuroscience; 2006 Nov; 143(1):155-63. PubMed ID: 16962718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuous activation of pituitary adenylate cyclase-activating polypeptide receptors elicits antipodal effects on cyclic AMP and inositol phospholipid signaling pathways in CATH.a cells: role of protein synthesis and protein kinases.
    Muller A; Lutz-Bucher B; Kienlen-Campard P; Koch B; Loeffler JP
    J Neurochem; 1998 Apr; 70(4):1431-40. PubMed ID: 9523559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pituitary adenylate cyclase activating polypeptide and PAC1 receptor signaling increase Homer 1a expression in central and peripheral neurons.
    Girard BM; Keller ET; Schutz KC; May V; Braas KM
    Regul Pept; 2004 Dec; 123(1-3):107-16. PubMed ID: 15518900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pituitary adenylate cyclase-activating peptide induces long-lasting neuroprotection through the induction of activity-dependent signaling via the cyclic AMP response element-binding protein-regulated transcription co-activator 1.
    Baxter PS; Martel MA; McMahon A; Kind PC; Hardingham GE
    J Neurochem; 2011 Aug; 118(3):365-78. PubMed ID: 21623792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Backup Mechanisms Maintain PACAP/VIP-Induced Arterial Relaxations in Pituitary Adenylate Cyclase-Activating Polypeptide-Deficient Mice.
    Ivic I; Fulop BD; Juhasz T; Reglodi D; Toth G; Hashimoto H; Tamas A; Koller A
    J Vasc Res; 2017; 54(3):180-192. PubMed ID: 28490016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Busto R; Sánchez-Chapado M; Guijarro LG; Prieto JC
    Cell Signal; 1999 Nov; 11(11):813-9. PubMed ID: 10617284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun.
    Delgado M; Munoz-Elias EJ; Kan Y; Gozes I; Fridkin M; Brenneman DE; Gomariz RP; Ganea D
    J Biol Chem; 1998 Nov; 273(47):31427-36. PubMed ID: 9813054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual effect of pituitary adenylate cyclase activating polypeptide on prostate tumor LNCaP cells: short- and long-term exposure affect proliferation and neuroendocrine differentiation.
    Farini D; Puglianiello A; Mammi C; Siracusa G; Moretti C
    Endocrinology; 2003 Apr; 144(4):1631-43. PubMed ID: 12639948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Physiological significance of pituitary adenylate cyclase-activating polypeptide (PACAP) in the nervous system].
    Hashimoto H
    Yakugaku Zasshi; 2002 Dec; 122(12):1109-21. PubMed ID: 12510388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel splice variants of type I pituitary adenylate cyclase-activating polypeptide receptor in frog exhibit altered adenylate cyclase stimulation and differential relative abundance.
    Alexandre D; Vaudry H; Grumolato L; Turquier V; Fournier A; Jégou S; Anouar Y
    Endocrinology; 2002 Jul; 143(7):2680-92. PubMed ID: 12072402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pituitary adenylyl cyclase-activating polypeptide controls the proliferation of retinal progenitor cells through downregulation of cyclin D1.
    Njaine B; Martins RA; Santiago MF; Linden R; Silveira MS
    Eur J Neurosci; 2010 Aug; 32(3):311-21. PubMed ID: 20646049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
    Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
    J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PACAP-38 Induces Transcriptomic Changes in Rat Trigeminal Ganglion Cells Related to Neuroinflammation and Altered Mitochondrial Function Presumably via PAC1/VPAC2 Receptor-Independent Mechanism.
    Takács-Lovász K; Kun J; Aczél T; Urbán P; Gyenesei A; Bölcskei K; Szőke É; Helyes Z
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VIP and PACAP analogs regulate therapeutic targets in high-risk neuroblastoma cells.
    de Boisvilliers M; Perrin F; Hebache S; Balandre AC; Bensalma S; Garnier A; Vaudry D; Fournier A; Festy F; Muller JM; Chadéneau C
    Peptides; 2016 Apr; 78():30-41. PubMed ID: 26826611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Signaling pathways in PACAP regulation of VIP gene expression in human neuroblastoma cells.
    Falktoft B; Georg B; Fahrenkrug J
    Neuropeptides; 2009 Oct; 43(5):387-96. PubMed ID: 19712974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pituitary adenylate cyclase-activating polypeptide (PACAP) alters parasympathetic neuron gene expression in a time-dependent fashion.
    Sumner AD; Margiotta JF
    J Mol Neurosci; 2008 Nov; 36(1-3):141-56. PubMed ID: 18594777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lot1 is a key element of the pituitary adenylate cyclase-activating polypeptide (PACAP)/cyclic AMP pathway that negatively regulates neuronal precursor proliferation.
    Fila T; Trazzi S; Crochemore C; Bartesaghi R; Ciani E
    J Biol Chem; 2009 May; 284(22):15325-38. PubMed ID: 19346254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuromodulatory effect of Gαs- or Gαq-coupled G-protein-coupled receptor on NMDA receptor selectively activates the NMDA receptor/Ca2+/calcineurin/cAMP response element-binding protein-regulated transcriptional coactivator 1 pathway to effectively induce brain-derived neurotrophic factor expression in neurons.
    Fukuchi M; Tabuchi A; Kuwana Y; Watanabe S; Inoue M; Takasaki I; Izumi H; Tanaka A; Inoue R; Mori H; Komatsu H; Takemori H; Okuno H; Bito H; Tsuda M
    J Neurosci; 2015 Apr; 35(14):5606-24. PubMed ID: 25855176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Disturbs Callus Formation.
    Józsa G; Fülöp BD; Kovács L; Czibere B; Szegeczki V; Kiss T; Hajdú T; Tamás A; Helyes Z; Zákány R; Reglődi D; Juhász T
    J Mol Neurosci; 2021 Aug; 71(8):1543-1555. PubMed ID: 31808034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells.
    Nagata A; Tanaka T; Minezawa A; Poyurovsky M; Mayama T; Suzuki S; Hashimoto N; Yoshida T; Suyama K; Miyata A; Hosokawa H; Nakayama T; Tatsuno I
    J Cell Physiol; 2009 Oct; 221(1):75-83. PubMed ID: 19496170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.